NIMIUM Therapeutics

NIMIUM Therapeutics is a Montreal-based life sciences startup focused on developing an innovative therapy to prevent and reverse the adverse effects of excessive calorie intake, promoting healthy aging. This research is based on the discovery of glycerol-3-phosphate phosphatase (G3PP), an enzyme that plays a central role in human glucose, lipid, and energy metabolism, contributing to the development of cardiometabolic diseases (CMD), type 2 diabetes, obesity, and other related health conditions. The company was founded by a team of experienced experts in obesity and diabetes as well as drug discovery and development.